BlackRock, Inc. filed Amendment No. 14 to Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of 19,373,309 shares of BioMarin Pharmaceutical Inc. common stock as of October 31, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 19,373,309 shares of BioMarin Pharmaceutical Inc. common stock.
  • Percent of class: The reported holdings represent 10.0% of BioMarin's outstanding common shares, according to the filing.
  • Sole voting power: BlackRock disclosed sole voting power over 18,549,911 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over 19,373,309 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The date of the event requiring the filing is listed as October 31, 2026.
  • Filing entity: The statement was signed by Spencer Fleming, Managing Director, on behalf of BlackRock, Inc., a Delaware-incorporated entity headquartered at 50 Hudson Yards, New York, NY 10001.

BlackRock's Amended Schedule 13G Filing on BioMarin Pharmaceutical

BlackRock, Inc. filed Amendment No. 14 to Schedule 13G with the Securities and Exchange Commission, disclosing its beneficial ownership position in BioMarin Pharmaceutical Inc. (issuer address: 770 Lindaro Street, San Rafael, CA 94901), with a triggering event date of October 31, 2026. The filing was submitted on November 4, 2026, and covers the common stock of BioMarin Pharmaceutical Inc. (CUSIP: 09061G101).

According to the filing, BlackRock beneficially owns an aggregate of 19,373,309 shares, representing 10.0% of the class. Of those shares, BlackRock reported sole voting power over 18,549,911 shares and sole dispositive power over the full 19,373,309 shares. No shared voting or dispositive power was reported.

The filing states that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates." The filing also notes that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of BIOMARIN PHARMACEUTICAL INC.," and that "no one person's interest in the common stock of BIOMARIN PHARMACEUTICAL INC is more than five percent of the total outstanding common shares." BlackRock is classified as a parent holding company (type HC) under the filing. Subsidiary identification is provided in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. disclosed through Amendment No. 14 to Schedule 13G that it beneficially owns 19,373,309 shares of BioMarin Pharmaceutical Inc. common stock, equal to 10.0% of the class, with sole voting power over 18,549,911 shares, as of October 31, 2026.